عرض بسيط للتسجيلة

المؤلفEl-Menyar, Ayman
المؤلفRizk, Nasser
المؤلفAl Nabti, Abdulrahman D.
المؤلفHassira, Sana Abu
المؤلفSingh, Rajvir
المؤلفAbdel Rahman, Mohamed Osman
المؤلفSuwaidi, Jassim Al
تاريخ الإتاحة2024-05-23T07:34:53Z
تاريخ النشر2009-04
اسم المنشورJournal of Cardiovascular Medicine
المعرّفhttp://dx.doi.org/10.2459/JCM.0b013e3283252b50
الاقتباسEl-Menyar, A., Rizk, N., Al Nabti, A. D., Hassira, S. A., Singh, R., Rahman, M. O. A., & Al Suwaidi, J. (2009). Total and high molecular weight adiponectin in patients with coronary artery disease. Journal of Cardiovascular Medicine, 10(4), 310-315.
الرقم المعياري الدولي للكتاب1558-2027
معرّف المصادر الموحدhttps://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=66149123619&origin=inward
معرّف المصادر الموحدhttp://hdl.handle.net/10576/55337
الملخصBACKGROUND: Serum adiponectin inversely correlates with the extent of coronary artery disease (CAD). OBJECTIVES: To investigate the clinical significance of measuring high molecular weight (HMW) adiponectin in addition to total adiponectin from different samples (peripheral veins and ostia of coronary arteries) in patients with CAD. METHODS: We studied 134 patients; 57 with acute coronary syndrome (ACS), 44 with stable angina and 33 healthy patients. Total and HMW adiponectin were measured in the coronary ostia and peripheral veins simultaneously. Venous levels of lipid profile, C-reactive protein, tumour necrosis factor-α, interleukin-6 and insulin were measured. RESULTS: Mean levels of HMW adiponectin in the coronary ostia were significantly correlated with the venous levels of total (r = 0.33, P = 0.002) and HMW (r = 0.37, P = 0.002) adiponectin. Mean levels of total and HMW adiponectin were lower in CAD patients versus controls (6.9 ± 0.5 versus 7.9 ± 0.7 μg/ml, P = 0.3 and 1.9 ± 0.2 versus 3.1 ± 0.3 μg/ml, P = 0.003). In the coronary ostia, levels of HMW adiponectin were higher in ACS than those with stable angina (1.1 ± 0.1 versus 0.8 ± 0.1 μg/ml, P = 0.2). In patients with CAD, levels of ostial adiponectin (total and HMW) were significantly lower in diabetic than non-diabetic patients (6.5 ± 0.8 versus 9.4 ± 1.1 μg/ml, P = 0.04 and 0.8 ± 0.12 versus 1.2 ± 0.1 μg/ml, P = 0.03). Mean levels of venous adiponectin (total and HMW) were non-significantly lower in diabetic patients (5.9 ± 0.7 versus 7.7 ± 0.7, P = 0.12 and 1.8 ± 0.4 versus 1.9 ± 0.1, P = 0.8). CONCLUSION: Measurement of HMW adiponectin and its ratio to total adiponectin may be a better marker for CAD than total adiponectin levels. Ostial levels of adiponectin in ACS may indicate re-distribution of adiponectin molecules towards the acute lesions. The low HMW adiponectin levels in diabetes mellitus may in part explain the worse outcome of CAD in diabetics. © 2009 Italian Federation of Cardiology.
اللغةen
الناشرWolters Kluwer Health
الموضوعAdiponectin
Anti-inflammatory
Coronary artery disease
HMW adiponectin
العنوانTotal and high molecular weight adiponectin in patients with coronary artery disease
النوعArticle
الصفحات310-315
رقم العدد4
رقم المجلد10
ESSN1558-2035


الملفات في هذه التسجيلة

الملفاتالحجمالصيغةالعرض

لا توجد ملفات لها صلة بهذه التسجيلة.

هذه التسجيلة تظهر في المجموعات التالية

عرض بسيط للتسجيلة